date:Aug 01, 2018
ug? asked Shapiros colleague, Marc Ullman, of Rivkin Radler.
Others have noted policy considerations in favor of making CBD lawful in supplements. For instance, in an interview before FDA approved Epidiolex, regulatory attorney Todd Harrison of Venable LLP cited evidence that CBD has health benefits beyond the treatment of disease, and he said GWs drug is for a narrow indication so it would be absurd from a policy standpoint to exclude its use for general health.
In reviewing a petition to aut